Comparative Pharmacology
Head-to-head clinical analysis: MYAMBUTOL versus P A S SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MYAMBUTOL versus P A S SODIUM.
MYAMBUTOL vs P.A.S. SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits arabinosyl transferase, an enzyme involved in cell wall synthesis of mycobacteria, leading to inhibition of cell growth.
P.A.S. (p-aminosalicylic acid) sodium is a bacteriostatic agent that competitively inhibits the synthesis of folic acid in Mycobacterium tuberculosis by antagonizing the incorporation of p-aminobenzoic acid (PABA) into dihydrofolate. It is selective for mycobacterial folate synthase.
15-25 mg/kg orally once daily (max 2.5 g/day); usual dose 20 mg/kg/day.
Oral: 4 g three times daily (total daily dose 12 g); IV: 12 g daily in 2-4 divided doses.
None Documented
None Documented
Terminal elimination half-life: 3-4 hours in normal renal function; prolonged to 7-15 hours in renal impairment.
1 hour (normal renal function); prolonged to 5-7 hours in anuria or severe renal impairment; clinical context: requires frequent dosing or renal dose adjustment
Renal: 50% unchanged drug; 20% as metabolite (ethambutol carboxylic acid); 15% as aldehyde intermediate; 15% unknown; fecal: <10%.
Renal (80% as active drug and metabolites, primarily acetylated form); fecal (minor; <10%)
Category C
Category C
Antitubercular Agent
Antitubercular Agent